Applied UV Declares Monthly Preferred Stock Dividend

Rhea-AI Summary

Applied UV, Inc. (AUVI) has announced a cash dividend of $0.21875 per share for holders of its 10.5% Series A Cumulative Perpetual Preferred Stock (AUVIP). The dividend will be paid on or about June 15, 2022, to shareholders of record at the close of business on June 3, 2022.

The company's technology focuses on pathogen elimination using UVC light and air purification solutions, aiming to address infection control across various sectors including healthcare and hospitality.

Positive

• Authorized cash dividend of $0.21875 per share for preferred stockholders.
• Focus on infection control technology in high-demand sectors such as healthcare and hospitality.

Negative

• None.

MOUNT VERNON, N.Y.--(BUSINESS WIRE)-- Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (“UVC”) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of Applied UV’s 10.5% Series A Cumulative Perpetual Preferred Stock.

Holders of the 10.5% Series A Cumulative Perpetual Preferred Stock (Nasdaq: AUVIP) shall receive a cash dividend equal to $0.21875 per share.

The return of capital will be paid on or about June 15, 2022, to respective holders of record at the close of business on June 3, 2022.

About Applied UV

Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections (“HAIs”). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company’s Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The Company’s patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen’s Airocide^® air purification devices are research backed, clinically proven and developed for NASA with assistance from the University of Wisconsin. Airocide^® is listed as an FDA Class II Medical device, utilizes a proprietary photocatalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide^® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities and homes. For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/; https://sterilumen.com/; https://www.airocide.com https://kesscience.com; https://scientificairmanagement.com and, https://munnworks.com/.

Forward-Looking Statements

The information contained herein may contain “forward‐looking statements.” Forward-looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward-looking statements are based on the Company’s current expectations and assumptions regarding its business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company’s actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005032/en/

For additional Company Information:

Applied UV Inc.

John F. Andrews

Applied UV CEO, Director

john.andrews@applieduvinc.com



Contacts

Brett Maas, Managing Principal

Hayden IR

brett@haydenir.com

(646) 536-7331

Source: Applied UV

FAQ

What is the dividend amount declared by Applied UV (AUVI)?

Applied UV declared a cash dividend of $0.21875 per share for its 10.5% Series A Cumulative Perpetual Preferred Stock.

When will the dividend be paid to shareholders of Applied UV (AUVIP)?

The dividend will be paid on or about June 15, 2022.

What is the record date for receiving the dividend from Applied UV (AUVI)?

The record date for receiving the dividend is June 3, 2022.

What technology does Applied UV focus on?

Applied UV focuses on pathogen elimination technology using UVC light and air purification systems.

What sectors does Applied UV target for its infection control technology?

Applied UV targets the healthcare, hospitality, commercial, and municipal markets with its infection control technology.